CDK9

(redirected from cyclin-dependent kinase 9)
Also found in: Wikipedia.

CDK9

A gene on chromosome 9q34.1 that encodes a cyclin-dependent kinase, which regulates cell cycle progression. CDK9 is part of the multiprotein complex TAK/P-TEFb, an elongation factor for RNA polymerase II-directed transcription, which acts by phosphorylating the C-terminal domain of a subunit of RNA polymerase II. 

Molecular pathology
HIV-1 Tat protein interacts with CDK9 and cyclin T, suggesting CDK9 may have a role in AIDS.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
The company added TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor entering into a Phase 1 study in patients with advanced solid tumours (NCT03604783).
Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9 currently being evaluated in Zella 201, a Phase II study in patients with relapsed or refractory MCL-1 dependent acute myeloid leukemia, AML, in combination with cytarabine and mitoxantrone (NCT02520011).
Biopharmaceutical company Probiodrug AG revealed on Friday the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor programme to AstraZeneca (LSE:AZN)(NYSE:AZN) for an undisclosed amount.
has tabulated preliminary data from Zella 201, an ongoing Phase 2 study evaluating the efficacy and safety of alvocidib, an investigational small molecule cyclin-dependent kinase 9 (CDK9) inhibitor, in combination with cytarabine and mitoxantrone in patients with relapsed or refractory myeloid cell leukemia 1 (MCL-1) dependent acute myeloid leukemia (AML), the company said.
Probiodrug AG (Probiodrug) announced today the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor programme to biopharmaceutical company AstraZeneca (LSE: AZN)(NYSE: AZN).
Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9, a protein important to the regulation of Myc.

Full browser ?